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BSTRACT
 
Background
 
Patients with chronic forms of major
depression are difficult to treat, and the relative effi-
cacy of medications and psychotherapy is uncertain.
 
Methods
 
We randomly assigned 681 adults with a
chronic nonpsychotic major depressive disorder to
12 weeks of outpatient treatment with nefazodone
(maximal dose, 600 mg per day), the cognitive be-
havioral-analysis system of psychotherapy (16 to 20
sessions), or both. At base line, all patients had
scores of at least 20 on the 24-item Hamilton Rating
Scale for Depression (indicating clinically significant
depression). Remission was defined as a score of 8 or
less at weeks 10 and 12. For patients who did not
have remission, a satisfactory response was defined
as a reduction in the score by at least 50 percent
from base line and a score of 15 or less. Raters were
unaware of the patients’ treatment assignments.
 
Results
 
Of the 681 patients, 662 attended at least
one treatment session and were included in the analy-
sis of response. The overall rate of response (both re-
mission and satisfactory response) was 48 percent in
both the nefazodone group and the psychotherapy
group, as compared with 73 percent in the combined-
treatment group (P<0.001 for both comparisons).
Among the 519 subjects who completed the study, the
rates of response were 55 percent in the nefazodone
group and 52 percent in the psychotherapy group, as
compared with 85 percent in the combined-treatment
group (P<0.001 for both comparisons). The rates of
withdrawal were similar in the three groups. Adverse
events in the nefazodone group were consistent with
the known side effects of the drug (e.g., headache,
somnolence, dry mouth, nausea, and dizziness).
 
Conclusions
 
Although about half of patients with
chronic forms of major depression have a response
to short-term treatment with either nefazodone or a
cognitive behavioral-analysis system of psychother-
apy, the combination of the two is significantly more
efficacious than either treatment alone. (N Engl J Med
2000;342:1462-70.)
 
©2000, Massachusetts Medical Society.
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RADITIONALLY thought of as an epi-
sodic, remitting illness, major depressive dis-
order often has a chronic course, with pro-
tracted episodes or incomplete remission
between episodes.
 
1-3
 
 At any given time, at least 3 per-
cent of the U.S. population suffers from chronic de-
pression.
 
4,5
 
 Chronic forms of major depression are
associated with more marked impairments in psy-
chosocial function and work performance,
 
6-8
 
 increased
health care utilization,
 
5,9
 
 and more frequent suicide
attempts and hospitalization
 
10
 
 than acute depression.
T
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Because they frequently begin early in life
 
11
 
 and are
often lifelong, chronic forms of major depression ac-
count for an inordinate proportion of the enormous
burden of illness associated with depression.
 
12
 
Several studies have demonstrated the efficacy of
antidepressants as both initial
 
13-16
 
 and maintenance
 
17,18
 
treatment for chronic forms of major depression, but
controlled clinical trials of sufficient size to examine
the efficacy of psychotherapy in chronic forms of
major depression are lacking.
 
19
 
 The combination of
pharmacotherapy and psychotherapy has been rec-
ommended as the treatment of choice for depression
by practice guidelines for psychiatrists
 
20
 
 and as the
treatment of choice for chronic forms of major de-
pression in primary care practice.
 
21
 
 However, the re-
sults of studies investigating whether combination
treatment is superior to single treatments have been
inconclusive.
 
22-24
 
We present the main findings from the initial (12-
week) phase of a long-term multicenter study com-
paring nefazodone alone, the cognitive behavioral-
analysis system of psychotherapy alone,
 
25,26
 
 or the two
in combination with regard to efficacy in the treat-
ment of patients with chronic forms of major de-
pression. Nefazodone has had demonstrated efficacy
in placebo-controlled trials and in numerous dou-
ble-blind trials of short-term treatment of major de-
pressive disorders,
 
27
 
 as well as a demonstrated ability
to prevent relapse after such treatment.
 
28
 
The cognitive behavioral-analysis system of psy-
chotherapy was developed specifically for the treat-
ment of chronic forms of major depression and pro-
duced promising results in a small, open trial.
 
29
 
 This
approach draws on many behavioral, cognitive, and
interpersonal techniques used in other forms of psy-
chotherapy.
 
30-32
 
 It teaches patients to focus on the
consequences of their behavior and to use a social
problem-solving algorithm to address interpersonal
difficulties. It is more structured and directive than
interpersonal psychotherapy
 
30
 
 and differs from cog-
nitive therapy
 
31
 
 by focusing primarily on interperson-
al interactions (including those with therapists). In
this type of psychotherapy, patients learn how their
cognitive and behavioral patterns produce and per-
petuate their interpersonal problems and learn how
to remedy maladaptive patterns of interpersonal be-
havior.
 
METHODS
 
Patients
 
We studied outpatients, recruited from 12 academic centers be-
tween June 1996 and December 1997, who fulfilled the criteria
for a chronic major depressive disorder (at least two years’ dura-
tion), a current major depressive disorder superimposed on a pre-
existing dysthymic disorder, or a recurrent major depressive dis-
order with incomplete remission between episodes in a patient
with a current major depressive disorder and a total duration of
continuous illness of at least two years. Diagnoses were based on
the 
 
Diagnostic and Statistical Manual of Mental Disorders,
 
 fourth
edition (DSM-IV),
 
33
 
 and were obtained with use of the Struc-
tured Clinical Interview for Axis I DSM-IV Disorders.
 
34
 
To be eligible for the study, the patients had to be between the
ages of 18 and 75 years and to have had a score of at least 20 on
the 24-item Hamilton Rating Scale for Depression (HRSD)
 
35
 
 at
screening and, after a two-week drug-free period, at base line. On
this scale, higher scores indicate more severe depression. Labora-
tory tests, electrocardiography (if clinically indicated), and physi-
cal examinations were performed at the time of screening. Pa-
tients were required to discontinue taking monoamine oxidase
inhibitors and fluoxetine at least four weeks before study entry,
depot neuroleptic agents at least six months before entry, and
other psychotropic medications at least two weeks before entry.
Patients were excluded from the study if they had any of the
following: a history of seizures, abnormal findings on electroen-
cephalography, severe head trauma, or stroke; evidence suggest-
ing they were at high risk for suicide; a history of psychotic symp-
toms or schizophrenia; bipolar disorder, an eating disorder (if it
had not been in remission for at least one year), obsessive–com-
pulsive disorder, or dementia; antisocial, schizotypal, or severe
borderline personality disorder; a principal diagnosis of panic, gen-
eralized anxiety, social phobia, or post-traumatic stress disorders or
any substance-related abuse or dependence disorder (except those
involving nicotine) within six months before the study began; ab-
sence of a response to a previous adequate trial of nefazodone or
a cognitive behavioral-analysis system of psychotherapy; absence
of a response to three previous adequate trials of at least two dif-
ferent classes of antidepressants or electroconvulsive therapy or to
two previous adequate trials of empirical psychotherapy in the
three years preceding the study; a serious, unstable medical con-
dition; or a positive urine screen for drugs of abuse. Women of
childbearing potential had to agree to use adequate contraception
during the study. Patients were not allowed to take anxiolytic
agents, sedatives, hypnotic agents, or any other types of sleep aids
(pharmacologic or behavioral) during the study.
 
Study Design
 
The institutional review board at each center approved the study.
All patients provided written informed consent. Patients who re-
mained eligible at the end of the two-week evaluation period were
randomly assigned, according to a central computerized random-
ization schedule, in a 1:1:1 ratio to receive nefazodone (Serzone,
Bristol-Myers Squibb), psychotherapy, or a combination of nefa-
zodone and psychotherapy. The Structured Clinical Interview for
Axis I DSM-IV Disorders and the HRSD were administered by
experienced clinical raters (study coordinators) certified to have a
high rate of interrater reliability and level of procedural integrity.
Each site implemented procedures to mask the patient’s treatment
assignment from the person who evaluated the results of the
HRSD, and the degree of adherence to these procedures was
monitored at each study visit. At all sites the rater was located at
a separate physical location so that he or she could not see pa-
tients arriving for or departing from treatment sessions.
Among the patients who received nefazodone, the initial dose
was 200 mg per day (100 mg twice a day) and was increased to
300 mg per day during the second week. Thereafter, the dose was
increased weekly in increments of 100 mg per day to a maximum
of 600 mg per day, to maximize the efficacy of the drug without
producing intolerable side effects. To remain in the study, patients
had to be receiving a dose of at least 300 mg per day by week 3.
Visits for medication were limited to 15 to 20 minutes. Psycho-
pharmacologists followed a published manual
 
36
 
 for clinical man-
agement (e.g., patients were questioned about the concomitant
use of medications and symptoms, side effects, and illnesses they
had had between visits). The psychopharmacologists were not al-
lowed to make formal psychotherapeutic interventions (such as
suggesting ways to cope with stressful life events).
The cognitive behavioral-analysis system of psychotherapy also
followed a manual
 
37
 
 specifying twice-weekly sessions during weeks
1 through 4 and weekly sessions during weeks 5 through 12. Twice-
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weekly sessions could be extended until week 8 if a patient was
not adequately performing a learned social problem-solving pro-
cedure according to the criteria.
Psychotherapists (persons who had at least two years’ experi-
ence after earning an M.D. or Ph.D. or at least five years’ experi-
ence after earning an M.S.W.) attended a two-day training work-
shop and met the criteria for mastery of treatment procedures
involved in the cognitive behavioral-analysis system of psycho-
therapy, as assessed by evaluation of their performance during
two videotaped pilot cases. All psychotherapy sessions conducted
during the study were videotaped, and supervisors reviewed the
videotapes weekly to assess the psychotherapists’ adherence to the
treatment procedures.
 
Outcome Measures
 
The score on the 24-item HRSD was the primary outcome.
The Global Assessment of Functioning Scale (Axis V in the DSM-
IV) was administered at base line, and the results were evaluated
by the same person who evaluated the HRSD results. Remission
was defined a priori as an HRSD score of no more than 8 at both
week 10 and week 12 for those who completed the 12-week pro-
tocol and at the time of withdrawal for those who did not com-
plete the study. A satisfactory therapeutic response was defined as
a reduction in the HRSD score by at least 50 percent from base
line to week 10 and week 12, with a total score of 15 or less at
these times but of more than 8 at week 10, week 12, or both for
those who completed the study and at the time of departure for
those who did not complete the study. The patients with these
favorable outcomes were combined to form a single response group.
All other patients were considered to have had no response.
 
Statistical Analysis
 
The base-line demographic and clinical characteristics of the
treatment groups were compared with the use of analysis of vari-
ance for continuous variables and the Cochran–Mantel–Haenszel
test for categorical variables, with site as the stratification variable.
Preliminary paired t-tests were conducted separately for each treat-
ment group to examine the significance of the changes in the
HRSD scores from base line to the end point.
No outcome data were collected on patients who withdrew from
the study after they withdrew, and a formal intention-to-treat analy-
sis thus could not be performed. The primary analysis was a mod-
ified intention-to-treat analysis that included all patients who at-
tended at least one treatment visit and who had at least one
assessment after the base-line evaluation. Patients who underwent
randomization but who did not return for a subsequent assess-
ment were therefore not included in this analysis. Given this mod-
ified approach, the main efficacy analysis was a piecewise mixed-
effects linear model that examined the relative differences between
treatments with respect to the rate of change in the HRSD score
(the linear slope) from base line to week 4 as one variable and
from week 4 to week 12 (or the last visit) as a second variable.
The a priori rationale for examining the first four weeks separately
was that the earliest antidepressant effects of nefazodone are likely
to occur at week 4 if a stable dosage has been achieved. Each
model estimated fixed effects with respect to treatment and site,
as well as the interactions between treatment and time. In addi-
tion, the models included a random intercept and a random slope.
Interactions between treatment and site were not significant and
therefore were not included in the models. The statistical signifi-
cance of additional terms included in successive models was de-
termined by the likelihood-ratio test. The error structure was spec-
ified as nonstationary autocorrelation in each model. There were
no interim analyses of the data.
In addition to the mixed-model analysis, we examined response
and remission rates that were based on the total HRSD score. We
used the Cochran–Mantel–Haenszel test to analyze these rates in
the modified intention-to-treat sample and among the patients
who completed the study (with site as the stratification variable).
We also performed an analysis of covariance of the change in total
HRSD scores from base line to the end point, with base-line
scores as the covariate, on these two samples. The model included
treatment and site as the main effects. The interactions between
treatment and site were again not significant and, hence, were not
included in the model. We made pairwise comparisons of the
means of the three treatment groups (adjusted for base-line val-
ues) using simple contrasts. Overall differences between treatments
were evaluated with use of an alpha level of 0.05, whereas pair-
wise comparisons used an alpha level of 0.0167 (0.05÷3) with
Bonferroni’s correction.
We used Fisher’s exact test to analyze the incidence of adverse
events and rate of discontinuation of treatment in the three
groups. All statistical tests were two-tailed. The data analysis was
done by a biostatistical data-management company (Statprobe,
Ann Arbor, Mich.), according to a plan devised by the authors.
The company was selected and paid by Bristol-Myers Squibb.
 
RESULTS
 
Base-Line Clinical and Demographic Characteristics
 
A total of 1035 patients were screened for the
study. Of the 354 who did not undergo randomiza-
tion, 235 (66 percent) did not meet the study crite-
ria, 47 (13 percent) withdrew their consent, and 72
(20 percent) were excluded for other reasons (e.g.,
failure to return for further evaluation or noncompli-
ance). A total of 681 patients underwent randomiza-
tion: 226 were assigned to receive nefazodone, 228
to receive psychotherapy, and 227 to receive com-
bined treatment (Table 1). Randomization was not
stratified according to site. At each site, approximate-
ly equal numbers of patients underwent randomiza-
tion to the three groups. However, there were no sig-
nificant differences among the groups with respect to
base-line demographic and clinical characteristics (Ta-
ble 2), either among the sites overall or within sites.
 
Treatment
 
For the modified intention-to-treat sample, the
mean (±SD) final daily dose of nefazodone was 466±
 
*The modified intention-to-treat sample consisted of all randomized pa-
tients who attended at least one treatment visit and who had at least one
efficacy assessment after the base-line evaluation.
 
T
 
ABLE
 
 1.
 
 S
 
TATUS
 
 
 
OF
 
 
 
THE
 
 681 P
 
ATIENTS
 
 
 
DURING
 
 
 
THE
 
 12-W
 
EEK
 
 
S
 
TUDY
 
, A
 
CCORDING
 
 
 
TO
 
 
 
THE
 
 T
 
REATMENT
 
 A
 
SSIGNMENT
 
.
 
S
 
TATUS
 
N
 
EFAZODONE
 
(N=226)
P
 
SYCHOTHERAPY
 
(N=228)
N
 
EFAZODONE
 
 
 
AND
 
P
 
SYCHOTHERAPY
 
(N=227)
 
number (percent)
 
Included in modified inten-
tion-to-treat sample*
220 (97) 216 (95) 226 (>99)
Completed the study 167 (74) 173 (76) 179 (79)
Withdrew from the study 59 (26) 55 (24) 48 (21)
Lack of efficacy 2 (1) 3 (1) 3 (1)
Adverse events 31 (14) 3 (1) 16 (7)
Withdrew consent 11 (5) 32 (14) 17 (7)
Protocol violation 2 (1) 2 (1) 0
Lost to follow-up 7 (3) 0 1 (<1)
Other reasons 6 (3) 15 (7) 11 (5)
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 16, 2015. For personal use only. No other uses without permission. 
 Copyright © 2000 Massachusetts Medical Society. All rights reserved. 
 NEFAZODONE, PSYCHOTHERAPY, AND THEIR COMBINATION FOR THE TREATMENT OF CHRONIC DEPRESSION
 
Volume 342 Number 20
 
·
 
1465
 
144 mg in the nefazodone group (data available for
216 patients) and 460±139 mg in the combined-
treatment group (221 patients). Among the patients
who completed the study and for whom data on dose
were available, the mean final daily dose of nefazo-
done was 520±100 mg among 92 patients with a
response in the nefazodone group and 479±111 mg
among the 152 patients with a response in the com-
bined-treatment group. The dose was 491±125 mg
among 73 patients without a response in the nefazo-
done group and 539±96 mg among the 27 patients
without a response in the combined-treatment group.
For the modified intention-to-treat sample, the av-
erage number of psychotherapy sessions was 16.0±4.7
among 216 patients in the psychotherapy group and
16.2±4.8 among 226 patients in the combined-
treatment group. Among those who completed the
study, the 90 patients with a response in the psycho-
therapy group and the 152 such patients in the com-
bined-treatment group attended a mean of 18.2±1.9
sessions, whereas the number was 17.7±1.9 among
the 83 patients in the psychotherapy group who had
no response and 17.9±1.4 among the 27 patients in
the combined-treatment group who had no response.
 
Efficacy
 
Analyses revealed a significant improvement with-
in patients in the HRSD scores from base line to
week 12 in the group of patients who completed the
study (P<0.001) and from base line to the last fol-
low-up visit in the modified intention-to-treat sam-
ple (P<0.001) in all three groups. The mixed-effects
piecewise linear regression examining the course of
the scores during the 12 weeks of the trial (Fig. 1)
showed that from base line through week 4, the av-
erage rate of improvement in the scores for patients
in the combined-treatment group was not significant-
ly different from the average rate of improvement in
the scores for patients in the nefazodone group (P=
0.39). However, the results of the analysis of the rate
 
*Plus–minus values are means ±SD. MDD denotes major depressive disorder.
†The score on the Global Assessment of Functioning Scale, which assesses the overall severity of psychiatric symptoms
and functional impairment, can range from 1 to 100. Scores ranging from 1 to 20 indicate a patient who is a danger to
others or to himself or herself. Scores ranging from 21 to 40 indicate a patient with moderate-to-severe impairments who
should be hospitalized. Scores ranging from 41 to 60 indicate a patient with serious, nonpsychotic symptoms that impair
function. Scores ranging from 61 to 80 indicate a patient with mild or transient symptoms who may require occasional
counseling and psychotherapy. Scores ranging from 81 to 100 indicate a person with good functioning who does not
require counseling.
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 B
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C
 
HARACTERISTIC
 
N
 
EFAZODONE
 
 
(N=226)
P
 
SYCHOTHERAPY
 
(N=228)
N
 
EFAZODONE
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P
 
SYCHOTHERAPY
 
(N=227)
A
 
LL
 
 P
 
ATIENTS
 
(N=681)
 
Female sex (%) 64.2 62.7 69.2 65.3
Age (yr) 42.2±11.0 43.2±10.8 44.4±10.3 43±10.7
White race (%) 87.2 91.7 92.5 90.5
Marital status (%)
Married or cohabiting 42.9 41.6 43.6 42.7
Single 27.4 30.3 23.8 27.2
Widowed 2.7 1.3 2.2 2.1
Divorced or separated 27.0 26.8 30.4 28.0
Depression diagnosis (%)
Chronic major depression 36.7 35.5 33.0 35.1
MDD with dysthymic disorder 42.9 39.9 44.1 42.3
Recurrent depression, with incomplete remission 
between episodes
20.4 24.6 22.9 22.6
Age at onset of MDD (yr) 25.6±13 27.5±13 27.1±13 26.7±13
Age at onset of dysthymia (yr) 17.8±13 19.7±14 20.3±14 19.3±14
Duration of current episode of MDD (yr) 7.5±9 7.8±10 8.0±9.5 7.8±9.6
Duration of current episode of dysthymia (yr) 22.3±15 22.5±15 24.2±16 23.0±15
History of anxiety disorder (%) 33.6 28.5 36.1 32.7
Diagnosis of coexisting personality disorder (%) 59.3 53.9 63.0 58.7
History of alcohol- or substance-abuse disorder (%) 34.5 33.3 31.7 33.2
Prior treatment with antidepressants (%) 57.5 59.5 63.6 60.2
Prior psychotherapy (%) 65.9 61.2 68.4 65.2
Prior treatment with both antidepressants and 
psychotherapy (%)
43.4 42.3 49.6 45.1
No prior treatment for depression (%) 19.9 22.0 17.1 19.7
Global Assessment of Functioning score† 53.8±5.4 53.9±5.7 53.6±5.6 54.0±5.6
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 16, 2015. For personal use only. No other uses without permission. 
 Copyright © 2000 Massachusetts Medical Society. All rights reserved. 
 1466
 
·
 
May 18, 2000
 
The New England Journal  of  Medicine
 
Figure 1.
 
 Mean Scores on the Hamilton Rating Scale for Depression during the 12-Week Study.
The results of the analysis of the rate of improvement in the scores as a regression slope were as fol-
lows: for base line through week 4, P<0.001 for the comparison of combined treatment and psycho-
therapy, P=0.004 for the comparison of nefazodone and psychotherapy, and P=0.39 for the compari-
son of combined treatment and nefazodone; and for weeks 4 through 12, P<0.001 for the comparison
of combined treatment and nefazodone and of psychotherapy and nefazodone and P=0.06 for the
comparison of combined treatment and psychotherapy.
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*The responses of two patients in the nefazodone group who completed the study could not be determined because no scores were available
for the Hamilton Rating Scale for Depression at week 10 or 12. In the modified intention-to-treat sample, no post-randomization scores were
available for two patients in the nefazodone group and four in the combined-treatment group. Remission was defined as a score of no more
than 8 at both week 10 and week 12 for those who completed the 12-week protocol and when they left the trial for those who did not
complete the study. A satisfactory response was defined as a reduction in the score by at least 50 percent from base line to week 10 and week
12, with a total score of 15 or less at these times but of more than 8 at week 10, week 12, or both for those who completed the study and
at the time of departure for those who did not complete the study.
 
TABLE 3. RATES OF RESPONSE AND REMISSION.*
GROUP NEFAZODONE PSYCHOTHERAPY
NEFAZODONE AND
PSYCHOTHERAPY P VALUE
NEFAZODONE VS.
PSYCHOTHERAPY 
NEFAZODONE VS.
COMBINED
TREATMENT
PSYCHOTHERAPY VS.
COMBINED
TREATMENT
no. of patients (%)
Modified intention-to-treat sample
No. of patients 220 216 226 
Response 105 (48) 103 (48) 165 (73) 0.92 <0.001 <0.001
Remission 64 (29) 72 (33) 109 (48) 0.37 <0.001 <0.001
Satisfactory response 41 (19) 31 (14) 56 (25) 0.21 0.10 0.004
No response 113 (51) 113 (52) 57 (25)
Patients who completed the study
No. of patients 167 173 179 
Response 92 (55) 90 (52) 152 (85) 0.57 <0.001 <0.001
Remission 36 (22) 41 (24) 75 (42) 0.64 <0.001 <0.001
Satisfactory response 56 (34) 49 (28) 77 (43) 0.30 0.07 0.004
No response 73 (44) 83 (48) 27 (15)
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of improvement in the scores as a regression slope
showed significant differences between the nefazodone
group and the psychotherapy group (P=0.004) and
between the combined-treatment group and the psy-
chotherapy group (P<0.001). From week 4 through
week 12, the average rate of improvement in the
HRSD scores for patients in the combined-treatment
group was significantly larger than the rate of im-
provement in scores for patients in the nefazodone
group (P<0.001). There was also a significant dif-
ference in the rate of improvement in scores between
the psychotherapy group and the nefazodone group
(P<0.001) but not between the combined-treatment
group and the psychotherapy group (P=0.06).
The overall rate of response was significantly high-
er in the combined-treatment group than in the nefa-
zodone group or the psychotherapy group in both
the modified intention-to-treat sample and the group
of patients who completed the study (P<0.001 for
all comparisons) (Table 3). For the modified inten-
tion-to-treat sample, the overall rates of response were
48 percent in the psychotherapy group (95 percent
confidence interval, 41.5 to 54.8 percent), 48 per-
cent in the nefazodone group (95 percent confidence
interval, 41.0 to 54.3 percent), and 73 percent in the
combined-treatment group (95 percent confidence
interval, 68.6 to 80.1 percent) at the time of the last
follow-up visit. Among the patients who completed
the 12 weeks of treatment, the overall rates of re-
sponse were 52 percent in the psychotherapy group
(95 percent confidence interval, 44.6 to 59.6 per-
cent), 55 percent in the nefazodone group (95 per-
cent confidence interval, 47.5 to 62.6 percent), and
85 percent in the combined-treatment group (95
percent confidence interval, 79.7 to 90.2 percent).
In both samples of patients, significantly more pa-
tients had a remission during combined treatment
than during treatment with nefazodone or psycho-
therapy alone (P<0.001 for all comparisons) (Table
3). In the modified intention-to-treat sample, the re-
mission rates were 33 percent in the psychotherapy
group, 29 percent in the nefazodone group, and 48
percent in the combined-treatment group. The re-
spective rates of remission among the patients who
completed the study were 24 percent, 22 percent,
and 42 percent.
An analysis of covariance revealed significant differ-
ences between treatment groups with respect to the
final HRSD scores for both the modified intention-to-
treat sample (Table 4) and in the patients who com-
pleted the study, with combined treatment more ef-
fective than either psychotherapy alone or nefazodone
alone (P<0.001 for all comparisons). To examine the
size of the differences between combined treatment
and treatment with nefazodone or psychotherapy
alone, we calculated effect sizes using Cohen’s d (the
difference between adjusted means divided by the
pooled standard deviation). The effect sizes calculat-
ed for the group of patients who completed the study
and for the modified intention-to-treat sample ranged
from 0.54 to 0.64 for the comparison of combined
treatment with the other two groups. There were no
significant differences at end point between the nefa-
zodone group and the psychotherapy group.
Rates of Discontinuation and Adverse Events
The rates of discontinuation were similar in the
three groups (P=0.46) (Table 1), with 24 percent of
*Plus–minus values are means ±SE. Higher scores on the 24-item test indicate more severe de-
pression. Values for week 12 represent data from patients who completed the study, whereas values
for the last follow-up visit represent data from the modified intention-to-treat sample.
†P<0.001 for the comparison with base-line score by the paired t-test.
‡The effect sizes were calculated as the difference between the adjusted means divided by the
pooled standard deviation.
TABLE 4. MEAN SCORES ON THE HAMILTON RATING SCALE FOR DEPRESSION 
AT BASE LINE, WEEK 12, AND THE LAST FOLLOW-UP VISIT.*
VARIABLE
NO. OF
PATIENTS BASE LINE WEEK 12
LAST FOLLOW-UP
VISIT
Score
Nefazodone
Psychotherapy
Nefazodone and psychotherapy
220
216
226
26.8±0.32
26.4±0.33
27.4±0.32
14.7±0.70†
15.1±0.69†
9.7±0.65†
15.8±0.64†
16.0±0.63†
10.8±0.63†
P value for comparison between groups
Nefazodone vs. psychotherapy
Nefazodone vs. combined treatment
Psychotherapy vs. combined treatment
0.68
<0.001
<0.001
0.79
<0.001
<0.001
Effect sizes (Cohen’s d) for pairwise
comparisons‡
Nefazodone vs. psychotherapy
Nefazodone vs. combined treatment
Psychotherapy vs. combined treatment
¡0.05
0.59
0.64
¡0.02
0.54
0.56
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all patients not completing the 12-week study. The
percentage of patients who dropped out because of
lack of efficacy was low (1 percent in each group).
The rate of discontinuation due to adverse events
was 14 percent in the nefazodone group, 7 percent
in the combined-treatment group, and 1 percent in
the psychotherapy group. The most common reason
for discontinuing psychotherapy was withdrawal of
consent (in 14 percent of patients). Of the 32 pa-
tients who withdrew their consent, 5 did not want
psychotherapy, 11 thought treatment was too time
consuming, and 4 wanted medication. Seventy-two
percent of the patients in the psychotherapy group
who withdrew their consent did so within the first
four weeks of treatment.
Table 5 lists the adverse events (whether or not
they were thought to be related to treatment) that
occurred in at least 10 percent of all patients. The ad-
verse events in the groups receiving nefazodone were
consistent with the known side effects of the medi-
cation, with headache, somnolence, dry mouth, nau-
sea, and dizziness being the most common. Weight
gain was rare, with no instances in the nefazodone
or psychotherapy group and an incidence of 3.1 per-
cent in the combined-treatment group. Sexual dys-
function (including impotence, psychosexual dysfunc-
tion, anorgasmia, and abnormal ejaculation) occurred
in 3.5 percent of the patients in the nefazodone group,
none of the patients in the psychotherapy group,
and 3.5 percent of the patients in the combined-
treatment group.
DISCUSSION
We found that treatment with a combination of
nefazodone and psychotherapy had significant ad-
vantages over treatment with nefazodone or psycho-
therapy alone. Despite the fact that the patients had
had active depression for many years and that many
had other psychiatric disorders as well, among the
patients who completed the study, 85 percent of the
patients in the combined-treatment group had a re-
sponse to treatment by week 12, as compared with
55 percent of patients in the nefazodone group and
52 percent of patients in the psychotherapy group.
The rates of response and remission in the com-
bined-treatment group were substantially higher than
those that might have been anticipated on the basis
of the outcomes of previous trials in similar patients.
By contrast, in the modified intention-to-treat sam-
ple, the rate of response of 48 percent in both the
nefazodone group and the psychotherapy group was
similar to the rates reported for treatment with ser-
traline (52 percent),13 imipramine (51 percent),13 and
desipramine (51 percent)18 in other studies of pa-
tients with chronic depression. The degree of supe-
riority of combination therapy over monotherapy, as
indicated by differences in the response rates and the
sizes of the effects, suggests that combined treatment
provides a clinically meaningful advantage. These re-
sults support previous recommendations,21 based on
clinical experience, for the use of both psychothera-
py and medication to treat patients with chronic de-
pression.
Nefazodone produced effects more rapidly than did
psychotherapy, with significant advantages evident in
the first four weeks, whereas psychotherapy had a
greater effect during the second part of the trial. By
week 12, the efficacy of the two approaches was sim-
ilar. Although patients who were receiving nefazodone
had higher frequencies of adverse events than those
receiving psychotherapy, the rates of withdrawal from
the study were similar in all three treatment groups.
The fact that the efficacy of combined treatment and
nefazodone was similar during the first four weeks of
the study but that combined treatment was more ef-
ficacious later in the study suggests that when medi-
cation and psychotherapy are administered together,
they continue to have independent rather than syn-
ergistic mechanisms of action.
A limitation of our study was the lack of a placebo
control. However, a placebo-controlled study of pa-
tients with either a chronic major depressive disorder
*Adverse events that were reported by at least 10 percent of all patients
are listed.
†Fisher’s exact test was used to test for differences among the three
groups.
TABLE 5. COMMON ADVERSE EVENTS.*
ADVERSE EVENT
NEFAZODONE
(N=225)
PSYCHO-
THERAPY
(N=221)
NEFAZODONE
AND PSYCHO-
THERAPY
(N=226)
P
VALUE†
percent
Headache 56 45 65 <0.001
Asthenia 17 6 20 <0.001
Pain 14 12 21 0.02
Abdominal pain 13 10 18 0.08
Infection 9 13 12 0.50
Back pain 8 10 12 0.23
Dry mouth 39 0 35 <0.001
Nausea 30 6 36 <0.001
Dyspepsia 21 12 19 0.02
Diarrhea 19 10 23 <0.001
Constipation 16 1 17 <0.001
Somnolence 40 1 36 <0.001
Dizziness 25 2 29 <0.001
Insomnia 19 8 19 0.004
Lightheadedness 12 <1 14 <0.001
Agitation 10 2 8 <0.001
Difficulty concentrating 9 1 10 <0.001
Pharyngitis 12 5 10 0.05
Sinusitis 12 11 10 0.89
Abnormal vision 15 <1 20 <0.001
Blurred vision 11 1 10 <0.001
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alone or a major depressive disorder plus dysthymia
reported a relatively low rate of response to placebo
(12 percent).14 In a study on the treatment of chron-
ic forms of depression, the use of a placebo control
would most likely greatly decrease the number of pa-
tients willing to participate, thereby reducing the gen-
eralizability of the findings.38
Another limitation, common to all studies of psy-
chotherapy, was our inability to mask patients and
therapists in the psychotherapy groups. To counter-
act this limitation, we had persons who were unaware
of the patients’ treatment assignments administer the
HRSD. However, the clinicians were obviously not
unaware of the treatment that patients were receiving.
Further limitations of our study include the restric-
tive exclusion criteria, which also reduced the gener-
alizability of the findings, and the rates of withdrawal
in conjunction with the lack of further data on pa-
tients after they withdrew. The slightly lower rate of
withdrawal in the combined-treatment group (21
percent) than in the nefazodone group (26 percent)
or the psychotherapy group (24 percent) may have
biased the outcome comparisons.
In summary, we found that the combination of
pharmacotherapy (nefazodone) and the cognitive be-
havioral-analysis system of psychotherapy was signif-
icantly more efficacious than either treatment alone
for outpatients with chronic forms of depression. The
rates of response to either treatment alone were sim-
ilar and were also similar to the rates reported in pre-
vious trials of antidepressants for the treatment of
chronic forms of depression in outpatients, indicat-
ing that at least one form of psychotherapy is effec-
tive in treating such patients. Although similarly ef-
fective, nefazodone produced effects more rapidly than
did psychotherapy.
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